{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:34:46Z","timestamp":1770287686908,"version":"3.49.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1128\/ASMCopyrightv2"},{"start":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T00:00:00Z","timestamp":1663632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Department of Pulmonary Immunology","award":["423500\/14000"],"award-info":[{"award-number":["423500\/14000"]}]},{"name":"University of Texas Systems STAR Award","award":["250439\/39411"],"award-info":[{"award-number":["250439\/39411"]}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R21AI148096"],"award-info":[{"award-number":["1R21AI148096"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI137080"],"award-info":[{"award-number":["R01 AI137080"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI150508"],"award-info":[{"award-number":["U01 AI150508"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2022,9,20]]},"abstract":"<jats:p>\n            The 12-month therapy duration for the treatment of\n            <jats:named-content content-type=\"genus-species\">Mycobacterium kansasii<\/jats:named-content>\n            pulmonary disease calls for more efficacious drugs for better treatment outcomes and to shorten the therapy duration. We performed (i) omadacycline MIC with\n            <jats:named-content content-type=\"genus-species\">M. kansasii<\/jats:named-content>\n            ATCC 12478 strain and 21 clinical isolates, (ii) dose-response study in the hollow fiber system model of\n            <jats:named-content content-type=\"genus-species\">M. kansasii<\/jats:named-content>\n            (HFS-\n            <jats:italic>Mkn<\/jats:italic>\n            ) with six human equivalent omadacycline daily doses to determine the optimal drug exposure for the maximal kill, and (iii) a second HFS-\n            <jats:italic>Mkn<\/jats:italic>\n            study to determine the efficacy of omadacycline (300\u2009mg\/day) plus moxifloxacin (600\u2009mg\/day) plus tedizolid (200\u2009mg\/day) combination regimen with standard regimen as comparator.\n          <\/jats:p>","DOI":"10.1128\/aac.00687-22","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T13:01:03Z","timestamp":1660741263000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":10,"title":["Omadacycline Pharmacokinetics\/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease"],"prefix":"10.1128","volume":"66","author":[{"given":"Sanjay","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"Quantitative Preclinical &amp; Clinical Sciences Department, Praedicare Inc., Dallas, Texas, USA"},{"name":"Hollow Fiber System &amp; Experimental Therapeutics Laboratories, Praedicare Inc., Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunavanthi D.","family":"Boorgula","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prem","family":"Shankar","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":true,"given":"Shashikant","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Immunology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_2_4_2","volume-title":"NUZYRA (omadacycline) for injection, for intravenous use; NUZYRA (omadacycline) tablets, for oral use.","author":"Food and Drug Administration U","year":"2018","unstructured":"Food and Drug Administration U. 2018. NUZYRA (omadacycline) for injection, for intravenous use; NUZYRA (omadacycline) tablets, for oral use."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-19"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01947-20"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"},{"key":"e_1_3_2_8_2","article-title":"Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection","volume":"11","author":"Minhas R","year":"2019","unstructured":"Minhas R, Sharma S, Kundu S. 2019. Utilizing the promise of omadacycline in a resistant, non-tubercular mycobacterial pulmonary infection. Cureus 11:e5112.","journal-title":"Cureus"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac068"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa415"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04441-14"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00248-18"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01553-20"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.5.571"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06354.x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz398"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-18"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.14.0120"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.45965-0"},{"key":"e_1_3_2_22_2","first-page":"516","article-title":"The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients","volume":"4","author":"Valainis GT","year":"1991","unstructured":"Valainis GT, Cardona LM, Greer DL. 1991. The spectrum of Mycobacterium kansasii disease associated with HIV-1 infected patients. J Acquir Immune Defic Syndr (1988) 4:516\u2013520.","journal-title":"J Acquir Immune Defic Syndr (1988)"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.5.1344-1346.1992"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-9-199811010-00004"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz309"},{"key":"e_1_3_2_26_2","unstructured":"Certara USA. 2020. Phoenix WinNonlin version 8.1. Certara USA Inc. Princeton NJ."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00687-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.00687-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T13:16:51Z","timestamp":1663679811000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.00687-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,20]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,20]]}},"alternative-id":["10.1128\/aac.00687-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.00687-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,20]]},"assertion":[{"value":"2022-05-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00687-22"}}